Why the study?
Does indium-111 antimyosin imaging accurately detect myocardial necrosis and predict clinical outcomes in patients with acute MI, myocarditis, or transplant rejection?
Does indium-111 antimyosin imaging accurately detect myocardial necrosis and predict clinical outcomes in patients with acute MI, myocarditis, or transplant rejection?
Answers are grounded in this paper and cite their sources.
Indium-111 antimyosin imaging is a promising noninvasive tool for detecting myocardial necrosis in acute MI, myocarditis, and transplant rejection.
Antimyosin is an Fab fragment of a murine monoclonal antibody directed against human heavy chain myosin. It is specific for myocyte necrosis. When linked via diethylenetriaminepentaacetic acid to indium-111, the agent has good imaging properties. With planar imaging, it has demonstrated high sensitivity and specificity for detecting and localizing acute myocardial infarction (MI). In addition, studies of dual isotope (indium-111 antimyosin/thallium-201) SPECT imaging at rest in the early in-hospital post-MI period appear to be predictive of further ischemic events. Antimyosin imaging also shows promise as a noninvasive tool to aid in the diagnosis and assessment of prognosis in cardiac transplant rejection and myocarditis. There is no evidence to date for allergic reactions to the murine protein.
No takes yet. Share an insight, caveat, or question.
Lynne L. Johnson (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: